IXHL:NASDAQIncannex Healthcare Inc. Analysis

IXHL trades around $3.70, just below its 20‑day SMA of $4.21 but near the 50‑day SMA of $3.69, indicating a modest short‑term pullback. The 14‑day RSI of 42 places the stock in a neutral momentum zone, while the MACD shows a bearish crossover with a negative histogram, reinforcing downside pressure. Beta of 2.6 and 30‑day volatility of 88% flag extreme price swings, and the max drawdown of ‑95% underscores historical fragility. The company reports zero revenue, negative EBITDA of $‑24.7 M, and negative operating cash flow, highlighting a cash‑burn profile, yet it holds $74.5 M in cash against minimal debt, giving a modest liquidity cushion. Its book‑value per share of $6.13 translates to a price‑to‑book of 0.60, suggesting the market price is discounted to book. Recent announcements of a partnership with the AASM Foundation for sleep‑apnea research and alignment with a White House executive order on psychedelic therapies could boost visibility and funding for the IHL‑42X and PSX‑001 pipelines, both in late‑stage trials. However, decreasing volume and a lack of earnings keep market support fragile, and the “Extreme Greed” reading on the Fear & Greed Index may be inflating short‑term buying interest despite weak fundamentals.